Intravesical Lactobacillus to Reduce Urinary Symptoms After Spinal Cord Injury

  • End date
    Aug 25, 2022
  • participants needed
  • sponsor
    Medstar Health Research Institute
Updated on 25 January 2021
spinal cord
spinal cord disorder
urinary symptoms
neurogenic bladder
intermittent catheterization


The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG) dose to be used to reduce urinary symptoms in a future clinical trial.


Urinary tract infection (UTI) is the most common outpatient infection world-wide, and for people with spinal cord injury (SCI) and neurogenic bladder (NB), it is the most common infection, secondary condition, cause for emergency room visits, and infectious cause of hospitalization. Despite its prevalence, attempts to ameliorate UTI among people with SCI are stymied by long-standing diagnostic challenges which arise from evidence gaps around "gold standard" diagnostic tests (urinalysis and urine culture) that have lower sensitivity and specificity for UTI in this population. A high prevalence of chronic inflammation leading to persistence of white blood cells (WBC) in the urine confounds the utility of WBC count, pyuria, and leukocyte esterase as biomarkers for UTI; nitrites in urine indicate the presence of only specific (but not all) organisms, many of which are present to a greater extent in the urine of people with SCI; and people with SCI have a high prevalence of asymptomatic bacteriuria. These physiologic changes render the gold standard diagnostic tests less useful for identifying UTI in persons with SCI.


2 urine samples (sampling at least 2 weeks apart) for urinalysis, urine culture, uNGAL, and NGS (16S rRNA and shotgun) under the same conditions. In addition to completing the USQNB-IC prior to urine collection, participants will complete the USQNB-IC 3 days after urine collection

SPECIFIC AIM 2 Intravesical LGG dose (group: high or low) will be obtained, USQNB-IC, urine collection for urinalysis, culture, NGAL and next generation sequencing as described above. And patient satisfaction questions.

Condition Neurogenic Bladder, Spinal Cord Injury, Myelopathy, Trauma, bladder disorder, Spinal Cord Injuries, Wounds, Spinal Cord Disorders, Bladder Disorders
Treatment Culturelle 10 Billion CFU Capsule (2 doses), Culturelle 10 Billion CFU Capsule (4 doses)
Clinical Study IdentifierNCT04373512
SponsorMedstar Health Research Institute
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Spinal Cord Injuries or bladder disorder or Myelopathy or Spinal Cord Injury or Neurogenic Bladder or Wounds or Trauma or Spinal Cord Disorders or Bla...?
Do you have any of these conditions: bladder disorder or Neurogenic Bladder or Bladder Disorders or Myelopathy or Spinal Cord Injuries or Wounds or Spinal Cord Disorders or Trauma or Spin...?
SCI at least 1-year duration
Neurogenic bladder
Utilizing intermittent catheterization for bladder management
Women must be premenopausal and not currently menstruating
Community dwelling

Exclusion Criteria

Use of prophylactic antibiotics
Instillation of intravesical antimicrobials to prevent UTI
Psychologic or psychiatric conditions influencing the ability to follow instructions
Use of oral or IV antibiotics within the past 2 weeks
Sexual activity within the previous 72 hours
Participation in another study with which results could be confounded
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note